Clinical Trials Logo

Clinical Trial Summary

During sepsis and septic shock the immune response can be overwhelming leading to excessive tissue damage, organ failure and death. Ideally, the inflammatory response is modulated leading to both adequate protection to invading pathogens as well as limitation of an exuberant immune response. In the last few years adenosine is proposed to have a central role in the modulation of inflammation. In unfavorable conditions such as hypoxia, ischemia or inflammation adenosine is quickly up-regulated; with concentrations up to tenfold in septic patients. Many animal studies have shown that adenosine is able to attenuate the inflammatory response and decrease mortality rates. Therefore, pharmacological elevation of the adenosine concentration is an potential target to attenuate inflammation and limit organ injury. Dipyridamole, an adenosine re-uptake inhibitor is able to increase the adenosine concentration and limit ischemia-reperfusion injury. In order to study the effects of dipyridamole on the inflammatory response we aim to use the so called human endotoxemia model. This model permits elucidation of key players in the immune response to a gram negative stimulus in vivo, therefore serving as a useful tool to investigate potential novel therapeutic strategies in a standardized setting.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT01091571
Study type Interventional
Source Radboud University
Contact
Status Completed
Phase Phase 4
Start date March 2010
Completion date October 2010

See also
  Status Clinical Trial Phase
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT02922673 - The Effects of Acetylsalicylic Acid on Immunoparalysis Following Human Endotoxemia N/A
Completed NCT01766414 - In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II Phase 3
Completed NCT04130321 - Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans N/A
Completed NCT02612480 - Ticagrelor in Human Endotoxemia Response to Human Endotoxemia N/A
Completed NCT01474629 - Probiotic Sport Study N/A
Completed NCT00246714 - Pathophysiology and Clinical Relevance of Endotoxin Tolerance in Humans Phase 1
Recruiting NCT06147440 - Different Dietary Patterns N/A
Recruiting NCT03901807 - Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study N/A
Completed NCT03754504 - Effects of Cranberry Powder Supplements on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03800277 - Effect of Cranberry and Agaves Extract on Microbiota and Intestinal Health N/A
Completed NCT00785018 - In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia N/A
Recruiting NCT00413348 - Type 2 Diabetes and the Effect of Probiotics N/A
Recruiting NCT00413465 - Study of Renal Blood Flow During Human Endotoxemia N/A
Completed NCT00412906 - Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls N/A
Completed NCT05752968 - Elevated Levels of Antibodies to Endotoxin Core in Hemodialysis Patients With Peripheral Artery Disease
Completed NCT01374711 - The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia N/A
Completed NCT00916448 - The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia N/A
Completed NCT00332267 - Cerebral Blood Flow and Metabolism During Hypoxia and Endotoxemia N/A
Completed NCT03482284 - Effect of Monosaccharides on Intestinal Barrier Function N/A